SANA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.778 SEK | +0.11% |
|
-2.31% | -55.66% |
| Mar. 01 | Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows | MT |
| Mar. 01 | Sector Update: Health Care Stocks Edge Higher Premarket Friday | MT |
| Sales 2023 | 16.84M 1.55M | Sales 2024 * | 62M 5.7M | Capitalization | 198M 18.15M |
|---|---|---|---|---|---|
| Net income 2023 | -95M -8.73M | Net income 2024 * | -37M -3.4M | EV / Sales 2023 | 15.3 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 3.19 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 23 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 69.76% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.11% | ||
| 1 week | -2.63% | ||
| Current month | -7.78% | ||
| 1 month | -5.02% | ||
| 3 months | -15.53% | ||
| 6 months | -68.14% | ||
| Current year | -55.66% |
1 week
1.75
1.89
1 month
1.751.99
Current year
1.754.90
1 year
1.7512.44
3 years
1.5725.20
5 years
1.5744.50
10 years
1.5755.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 10-12-31 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 10-12-31 |
Jørgen Drejer
FOU | Founder | 69 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 10-12-31 |
| Director/Board Member | 66 | 14-12-31 | |
Anna Ljung
BRD | Director/Board Member | 44 | 18-01-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.778 | +0.11% | 202 982 |
| 24-04-23 | 1.776 | -1.33% | 158,143 |
| 24-04-22 | 1.8 | -2.70% | 242,598 |
| 24-04-19 | 1.85 | -1.91% | 320,759 |
| 24-04-18 | 1.886 | +3.29% | 179,686 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:23 am EDT
More quotes
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Calendar
2024-05-22
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -55.66% | 18.25M | |
| -1.46% | 105B | |
| +3.61% | 97.5B | |
| +1.86% | 22.19B | |
| -16.33% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.59% | 14.52B | |
| +5.88% | 14.09B | |
| +21.97% | 10.99B |
- Stock Market
- Equities
- SANION Stock
